Barrett Frederick S, Griffiths Roland R
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD, 21224, USA.
Department of Neuroscience, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD, 21224, USA.
Curr Top Behav Neurosci. 2018;36:393-430. doi: 10.1007/7854_2017_474.
This chapter begins with a brief review of descriptions and definitions of mystical-type experiences and the historical connection between classic hallucinogens and mystical experiences. The chapter then explores the empirical literature on experiences with classic hallucinogens in which claims about mystical or religious experiences have been made. A psychometrically validated questionnaire is described for the reliable measurement of mystical-type experiences occasioned by classic hallucinogens. Controlled laboratory studies show that under double-blind conditions that provide significant controls for expectancy bias, psilocybin can occasion complete mystical experiences in the majority of people studied. These effects are dose-dependent, specific to psilocybin compared to placebo or a psychoactive control substance, and have enduring impact on the moods, attitudes, and behaviors of participants as assessed by self-report of participants and ratings by community observers. Other studies suggest that enduring personal meaning in healthy volunteers and therapeutic outcomes in patients, including reduction and cessation of substance abuse behaviors and reduction of anxiety and depression in patients with a life-threatening cancer diagnosis, are related to the occurrence of mystical experiences during drug sessions. The final sections of the chapter draw parallels in human neuroscience research between the neural bases of experiences with classic hallucinogens and the neural bases of meditative practices for which claims of mystical-type experience are sometimes made. From these parallels, a functional neural model of mystical experience is proposed, based on changes in the default mode network of the brain that have been observed after the administration of classic hallucinogens and during meditation practices for which mystical-type claims have been made.
本章首先简要回顾了神秘主义类型体验的描述与定义,以及经典致幻剂与神秘体验之间的历史联系。接着,本章探讨了有关经典致幻剂体验的实证文献,其中涉及到对神秘或宗教体验的宣称。文中描述了一种经过心理测量验证的问卷,用于可靠地测量由经典致幻剂引发的神秘主义类型体验。对照实验室研究表明,在能有效控制期望偏差的双盲条件下,裸盖菇素能使大多数受研究对象产生完整的神秘体验。这些效应具有剂量依赖性,与安慰剂或精神活性对照物质相比,对裸盖菇素具有特异性,并且通过参与者的自我报告和社区观察者的评分评估,对参与者的情绪、态度和行为产生持久影响。其他研究表明,健康志愿者的持久个人意义以及患者的治疗效果,包括药物滥用行为的减少和戒除,以及对患有危及生命的癌症诊断患者焦虑和抑郁的减轻,都与药物治疗期间神秘体验的发生有关。本章的最后部分在人类神经科学研究中,对经典致幻剂体验的神经基础与有时声称具有神秘主义类型体验的冥想练习的神经基础进行了比较。基于这些比较,提出了一种神秘体验的功能性神经模型,该模型基于在服用经典致幻剂后以及在声称具有神秘主义类型体验的冥想练习期间观察到的大脑默认模式网络的变化。